All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Reduced-intensity transplantation in older patients with acute myeloblastic leukemia: NCRI AML16 trial
A summary of the latest results, comparing RIC transplantation with chemotherapy in older patients, that were recently published in Haematologica...
Visual Abstract | Eprenetapopt plus azacitidine as a post-allo-HCT treatment for patients with TP53-mutated AML and MDS: Results from a phase II trial
A representing key data from a phase II trial evaluating eprenetapopt plus azacitidine as a...
Are you a healthcare professional? What is your specialty?
Please select or type your specialty
By sharing this information, you can help ensure we continue to develop content that is of most relevance for our audience.
Thank you for submitting.